We are thrilled to announce a major milestone in our journey to become a vertically integrated cannabis company serving the needs of the industry in Canada, and abroad.
2023 has been a remarkable year for Klonetics marked by significant milestones that have paved the way for our expansion and growth. Most recently, we secured a two year contract with a large licensed producer to custom grow premium craft cannabis. This partnership extends their market reach in the premium craft cannabis category and allows them to offer new and exciting cultivars. The deal will showcase the best genetics in the Klonetics library and demonstrate our commitment to superior quality plants meticulously nurtured from tissue to flower.
Additionally, this year we broadened our global reach by establishing a strategic partner facility in Portugal. This expansion was complemented by a groundbreaking agreement with an International medical cannabis company to provide custom flower, further solidifying our position as a global cannabis company. Earlier this month, we also successfully completed our IMC-GAP certification.
Custom contract growing of premium flower represents a new and increasing line of business for Klonetics and will continue to grow in 2024. As Klonetics begins to support more customers globally, we will continue to address the unique needs of each market by providing fresh and stable premium genetics that drive meaningful profit for our customers, while exceeding regulatory requirements in each region we operate in.
At Klonetics, we're not just growing cannabis; we're cultivating excellence, scientific innovation, and a brighter future for the global cannabis industry.
Stay connected with us for more exciting updates on our
LinkedIn page.
Share this article with your network:
This three-year project aims to develop the optimal media formulations and transformation process to generate the highest-value cannabis plants in the market. We have examined the response of different cannabis genotypes to tissue culture media formations to develop tissue culture media formulations tailored for cannabis genotypes. We will be evaluating upon flowering of the rooted clones of the selected tissue culture plants, flowers should have equal to or better yield and potency than traditional clone production and cultivation of cannabis plants.
Another goal of this project is to develop a genetic transformation procedure for cannabis from callus and/orprotoplast regeneration optimization. This protocol will be used to increase pathogen resistance and improve quality traits like yield in cannabis plants.
Abstract: First, the project will focus on the genetic structure of a subset of Klonetic's extensive germplasm collection by conducting a large genotyping-by-sequencing (GBS) experiment and single nucleotide polymorphism (SNP) data analyses. Second, the project will perform phenotypic analyses at the CLS (Canadian Light Source) to quantify important biochemical and agronomic traits associated with trichomes and seed formation.
Description: Due to longstanding restrictions, our basic knowledge of Cannabis is far behind other crops (Clarke and Merlin 2017). Hence, many of the claims made by the industry regarding the various applications of Cannabis require advanced molecular, pharmaceutical, and agronomic research, all of which require an in-depth understanding of its evolutionary history, genetic structure, biochemical variability, and reproductive diversity. This research proposed here provides a roadmap combining modern genomics tools to establish a solid business model for cannabis genetic improvement to cater to future needs of the medical and recreational market in Canada.
Abstract: An integrative research project aimed at studying the pollen generated by a core set of Cannabis accessions is proposed The project will develop phenotypic analyses of pollen at the CLS whereby both surface and internal structures can be qualified and quantified. The project will focus on identifying X and Y chromosomes carrying pollen, as this could be used in a sorting procedure for the directed breeding of female plants.
Description: Medicinal cannabis is a treasure trove of phytochemicals with more than 110 different cannabinoids, terpenes, and flavonoids. Major phytoactive compounds of interest are delta-9 tetrahydrocannabinolic acid (THCA) and cannabidolic acid (CBDA) for their medicinal effects. Varying profiles of THC, CBD, and terpenes with a range of 20-30% total cannabinoids in cannabis products provide numerous opportunities for treating different diseases (medicinal applications) and various organoleptic properties in combination with THC (recreational applications). Most of the traditional cannabis breeding in North America used hybrid or varietal approaches, whereas little efforts have been made to apply modern genomics tools and breeding methods for cannabis genetic improvement and innovation.
All Rights Reserved | Klonetics Plant Science Inc.